CSIMarket Company Name, Ticker, Industry, else..
 
Viracta Therapeutics Inc   (NASDAQ: VIRX)
 

Viracta Therapeutics Inc's Suppliers Performance

VIRX's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
VIRX Costs vs Sales of Suppliers Growth

• More on VIRX Suppliers






Viracta Therapeutics Inc's Comment on Supply Chain


The company utilizes contract manufacturers to produce materials in compliance with FDA, EMA, and other regulatory standards. Failure by these manufacturers to maintain quality control or regulatory approvals may require the company to secure alternative manufacturing facilities, potentially causing delays in product development and commercialization. The company holds a license agreement with ImmunityBio, Inc., formerly NantKwest, Inc., for the development and commercialization of nanatinostat. This agreement includes collaboration on clinical trials and regulatory approvals, with ImmunityBio responsible for conducting the necessary studies and trials to obtain regulatory approval for the licensed products.

Viracta Therapeutics Inc's Comment on Supply Chain


The company utilizes contract manufacturers to produce materials in compliance with FDA, EMA, and other regulatory standards. Failure by these manufacturers to maintain quality control or regulatory approvals may require the company to secure alternative manufacturing facilities, potentially causing delays in product development and commercialization. The company holds a license agreement with ImmunityBio, Inc., formerly NantKwest, Inc., for the development and commercialization of nanatinostat. This agreement includes collaboration on clinical trials and regulatory approvals, with ImmunityBio responsible for conducting the necessary studies and trials to obtain regulatory approval for the licensed products.







VIRX's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Viracta Therapeutics Inc 0.39 0.00 -43.29 12
SUBTOTAL 0.00 0.00 0.00 -


Sources: Viracta Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Viracta Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.